/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED
STATES/
HOUSTON and VANCOUVER, July 13,
2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical
company focused on the development of novel small molecule drugs for the treatment of prostate cancer, is pleased to announce
today that the Company has priced its previously announced offering of equity securities (the "Proposed Offering").
Pursuant to the Proposed Offering, ESSA intends to issue units of the Company ("Units") at a price of US$0.44 per Unit. Each Unit will be comprised of one common share of the Company (a "Common Share") and one
common share purchase warrant (a "Warrant"). Each Warrant will be exercisable at a price of US$0.51 and entitle the holder thereof to acquire one common share of the Company (a "Warrant Share") for a
period of five years following the closing of the Proposed Offering. The number of Units to be sold and aggregate size of the
Proposed Offering will be determined following completion of the marketing effort.
The Proposed Offering will be undertaken on a best efforts basis pursuant to the terms and conditions of an agency agreement
to be entered into between the Company and Bloom Burton Securities Inc. as the Company's sole agent for the Proposed Offering in
Canada (the "Canadian Agent"). The Units may also be offered for sale in the United States through United States registered broker-dealers appointed
by the Canadian Agent as sub-agents. The selling group will be paid a cash commission equal to 7.0% of the gross proceeds of the
Proposed Offering (except in respect of Units issued to certain specified purchasers, in which case the cash commission will be
reduced to 3.5%). The price of the Units was determined by negotiation between the Company and the Canadian Agent in the context
of the market.
The Company intends to use the net proceeds of the Proposed Offering for the Company's pre-clinical and clinical development
of the prostate cancer programs and for working capital and other general corporate purposes.
The Company will apply to list the Common Shares and the Warrant Shares on the Toronto Stock Exchange ("TSX"). Listing will be
subject to satisfying all of the requirements of the TSX and the NASDAQ Capital Market ("NASDAQ"). The Company expects to close
the Proposed Offering on or about July 20, 2017, or such other date as may be mutually agreed to by
the Company and the Canadian Agent, subject to satisfaction of customary closing conditions, including, but not limited to, the
receipt of all necessary stock exchange approvals, such as the final approval of the TSX and NASDAQ.
The Proposed Offering is to be effected in each of the provinces of British Columbia,
Alberta and Ontario by way of a prospectus supplement to ESSA's
base shelf prospectus dated December 22, 2015 and elsewhere on a private placement basis.
The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S.
Securities Act"), or any state securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of,
persons in the United States or "U.S. persons," as such term is defined in Regulation S
promulgated under the U.S. Securities Act ("U.S. Persons"), except in compliance with the registration requirements of the U.S.
Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does
not constitute an offer to sell or a solicitation of an offer to buy any of the Company's securities to, or for the account of
benefit of, persons in the United States or U.S. Persons.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the
treatment of castrate resistant prostate cancer ("CRPC") in patients whose disease is progressing despite treatment with current
therapies. ESSA believes that its product candidate, EPI-506, can significantly expand the interval of time in which patients
suffering from CRPC can benefit from hormone-based therapies. Specifically, EPI-506 acts by disrupting the androgen receptor
("AR") signaling pathway that drives prostate cancer growth. EPI-002, the primary metabolite of EPI-506, prevents AR
transcriptional activity by binding selectively to the N-terminal domain ("NTD") of the AR. A functional NTD is essential for
transactivation of the AR. In preclinical studies, blocking the NTD has demonstrated the capability to overcome the known
AR-dependent mechanisms of CRPC. ESSA was founded in 2009.
About Prostate Cancer
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer
death worldwide (Globocan, 2012). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or
blocking androgen action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially
sensitive to medical or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of
testosterone generally represents a transition to the lethal variant of the disease, mCRPC, and most patients ultimately succumb
to the illness. The treatment of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional
treatment options are needed to improve clinical outcomes in patients, particularly those who fail existing treatments including
abiraterone or enzalutamide, or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally
experience continued disease progression, worsening pain, leading to substantial morbidity and limited survival rates. In both in
vitro and in vivo animal studies, ESSA's novel approach to blocking the androgen pathway has been shown to be effective in
blocking tumor growth when current therapies are no longer effective.
Forward-Looking Statement Disclaimer
This release contains certain information which, as presented, constitutes "forward-looking information" within the
meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking
information involves statements that relate to future events and often addresses expected future business and financial
performance, containing words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an
action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and includes, but is
not limited to, statements about the composition of the Units, the timing of the closing of the Proposed Offering, the
satisfaction and timing of the receipt of required stock exchange approvals and other conditions to closing of the Proposed
Offering, the jurisdictions in which the Units will be offered and the intended use of proceeds of the Proposed Offering.
Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which
are beyond the ability of ESSA to control or predict, and which may cause ESSA's actual results, performance or achievements to
be materially different from those expressed or implied thereby. Such statements reflect ESSA's current views with respect to
future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that,
while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific,
business, economic, competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA
may make various material assumptions, including but not limited to (i) the accuracy of ESSA's financial projections; (ii) the
Phase 1 portion of the Phase 1/2 clinical trial proceeding as expected; (iii) obtaining positive results of clinical trials; (iv)
obtaining necessary regulatory approvals; and (v) general business, market and economic conditions.
Forward-looking information is developed based on assumptions about such risks, uncertainties and other factors set
out herein and in ESSA's Annual Report on Form 20-F dated December 14, 2016 under the heading "Risk
Factors", a copy of which is available on ESSA's profile at the SEDAR website at www.sedar.com, ESSA's profile on EDGAR at www.sec.gov, and as
otherwise disclosed from time to time on ESSA's SEDAR profile. Forward-looking statements are made based on management's beliefs,
estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking
statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable
Canadian and United States securities laws. Readers are cautioned against attributing undue
certainty to forward-looking statements.
SOURCE ESSA Pharma Inc
View original content with multimedia: http://www.newswire.ca/en/releases/archive/July2017/13/c2631.html